Addressing the crime reduction and harm reduction divide - promoting opioid agonist therapy in the US drug courts

Randall Brown, Nat Wright, Brienna Dey, Amelia Baltes, Margaret Linden, Lisa Szela

Abstract


The reduction of harm due to illicit drug use is a common goal of law enforcement and public health sectors.  However, law enforcement and public health policies to achieve this goal are often at odds.  The burgeoning drug court model in the U.S. provides a unique opportunity to blend law enforcement and treatment approaches to intervene at the drugs-crime nexus. In the U.S., however, vocal resistance to modalities thought of as “harm reduction,” and an emphasis upon supply reduction over demand reduction may hinder realization of the full potential for the drug court treatment model. To illustrate the current socio-political environment in the U.S., this paper begins by examining contributions to the reduction of drug-related harms by the law enforcement and healthcare sectors.  Through the example of opioid substitution for opioid use disorders, we then posit a framework under which these often disparate entities may engage in cooperative policies to reduce the individual and societal harms caused by illicit drug use.

Keywords


opioid; opioid use disorder; drug court; drug treatment court; opioid agonist therapy; medication-assisted treatment

Full Text:

 Subscribers Only

References


United States Code. Penalties for simple possession. Title 21 Chapter 13, (2010).

Harm Reduction Coalition -. Available at: http://harmreduction.org/. (Accessed: 10th June 2016)

APA. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. (American Psychiatric Association, 2015).

Dinwiddie S, Reich T. Genetic and Family Studies in Psychiatric Illness and Alcohol and Drug Dependence. J. Addict. Dis. 12, 17–27 (1993).

Rounsaville BJ, Kosten TR, Weissman MM & et al. Psychiatric disorders in relatives of probands with opiate addiction. Arch. Gen. Psychiatry 48, 33–42 (1991).

Agrawal, A. & Lynskey, M. T. Are there genetic influences on addiction: evidence from family, adoption and twin studies. Addict. Abingdon Engl. 103, 1069–1081 (2008).

Herman, A. I., DeVito, E. E., Jensen, K. P. & Sofuoglu, M. Pharmacogenetics of nicotine addiction: role of dopamine. Pharmacogenomics 15, 221–234 (2014).

Bauer, I. E., Soares, J. C. & Nielsen, D. A. The role of opioidergic genes in the treatment outcome of drug addiction pharmacotherapy: A systematic review. Am. J. Addict.. 24, 15–23 (2015).

DiLeone, R. J., Georgescu, D. & Nestler, E. J. Lateral hypothalamic neuropeptides in reward and drug addiction. Life Sci. 73, 759–768 (2003).

Robbins, T. W., Cador, M., Taylor, J. R. & Everitt, B. J. Limbic-striatal interactions in reward-related processes. Neurosci. Biobehav. Rev. 13, 155–162 (1989).

Volkow, N. D., Fowler, J. S. & Wang, G.-J. The addicted human brain: insights from imaging studies. J. Clin. Invest. 111, 1444–1451 (2003).

Winder, D. G., Egli, R. E., Schramm, N. L. & Matthews, R. T. Synaptic Plasticity in Drug Reward Circuitry. Curr. Mol. Med. 2, 667–676 (2002).

Goodman, A. Neurobiology of addiction. An integrative review. Biochem. Pharmacol. 75, 266–322 (2008).

Lu, Y.-L. & Richardson, H. N. Alcohol, stress hormones, and the prefrontal cortex: a proposed pathway to the dark side of addiction. Neuroscience 277, 139–151 (2014).

Acton, G. S. Measurement of Impulsivity in a Hierarchical Model of Personality Traits: Implications for Substance Use. Subst. Use Misuse 38, 67–83 (2003).

Rosen, C. S., Ouimette, P. C., Sheikh, J. I., Gregg, J. A. & Moos, R. H. Physical and sexual abuse history and addiction treatment outcomes. J. Stud. Alcohol 63, 683–687 (2002).

Turner, R. J. The Pursuit of Socially Modifiable Contingencies in Mental Health. J. Health Soc. Behav. 44, 1–17 (2003).

Smith, J. L., Mattick, R. P., Jamadar, S. D. & Iredale, J. M. Deficits in behavioural inhibition in substance abuse and addiction: a meta-analysis. Drug Alcohol Depend. 145, 1–33 (2014).

Coskunpinar, A. & Cyders, M. A. Impulsivity and substance-related attentional bias: a meta-analytic review. Drug Alcohol Depend. 133, 1–14 (2013).

MacKillop, J. et al. Delayed reward discounting and addictive behavior: a meta-analysis. Psychopharmacology (Berl.) 216, 305–321 (2011).

Best, D., Hernando, R., Gossop, M., Sidwell, C. & Strang, J. Getting by with a little help from your friends: The impact of peer networks on criminality in a cohort of treatment-seeking drug users. Addict. Behav. 28, 597–603 (2003).

Musher-Eizenman, D. R., Holub, S. C. & Arnett, M. Attitude and Peer Influences on Adolescent Substance Use: The Moderating Effect of Age, Sex, and Substance. J. Drug Educ. 33, 1–23 (2003).

Walton, M. A., Blow, F. C., Bingham, C. R. & Chermack, S. T. Individual and social/environmental predictors of alcohol and drug use 2 years following substance abuse treatment. Addict. Behav. 28, 627–642 (2003).

Leach, D. & Kranzler, H. R. An Interpersonal Model of Addiction Relapse. Addict. Disord. Their Treat. 12, 183–192 (2013).

Seo, D.-C. & Huang, Y. Systematic review of social network analysis in adolescent cigarette smoking behavior. J. Sch. Health 82, 21–27 (2012).

Conrad, P. & Schneider, J. W. in Deviance and Medicalization: From Badness to Sickness 121–130 (Temple University Press, 2010).

Milhet, M., Bergeron, D. H. & Hunt, M. G. Drugs and Culture: Knowledge, Consumption, and Policy. (Ashgate Publishing, Ltd., 2013).

Anderson, T., Swan, H. & Lane, D. C. Institutional Fads and the Medicalization of Drug Addiction. Sociol. Compass 4, 476–494 (2010).

Rosenbaum, M. The Demedicalization of Methadone Maintenance. J. Psychoactive Drugs 27, 145–149 (1995).

Reagan, R. Broadcast from the White House Residence. (1986).

Office of National Drug Control Policy. National Drug Control Budget - FY 2015 Funding Highlights. 7 (The White House, 2014).

Carson, E. A. Prisoners in 2014. 17 (U.S. Department of Justice, 2015).

Taxy, S., Samuels, J. & Adams, W. Drug offenders in federal prison: Estimates of characteristics based on linked data. (US Department of Justice, Bureau of Justice Statistics, 2015).

Beckett, K., Nyrop, K. & Pfingst, L. Race, Drugs, and Policing: Understanding Disparities in Drug Delivery Arrests*. Criminology 44, 105–137 (2006).

Mitchell, O. & Caudy, M. S. Examining Racial Disparities in Drug Arrests. Justice Q. 32, 288–313 (2015).

Mitchell, O. & Caudy, M. S. Race Differences in Drug Offending and Drug Distribution Arrests. Crime Delinquency

Substance Abuse and Mental Health Services Administration, enter for. Substance Use and Mental Health Estimates from the 2013 National Survey on Drug Use and Health: Overview of Findings. (2014).

National Institute on Drug Abuse. High School and Youth Trends. (National Institutes of Health; U.S. Department of Health and Human Services., 2014).

Substance Abuse and Mental Health Services Administration, enter for & Center for Behavioral Health Statistics and Quality. Highlights of the 2011 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visit. (2013).

US Drug Enforcement Administration. 2015 National Drug Threat Assessment Summary. (US Department of Justice, 2015).

National Institute on Drug Abuse. Trends & Statistics. (National Institutes of Health, 2015).

Lenke, L. & Olsson, B. Swedish Drug Policy in the Twenty-First Century: A Policy Model Going Astray. Ann. Am. Acad. Pol. Soc. Sci. 582, 64–79 (2002).

Wallace, J. M. The Social Ecology of Addiction: Race, Risk, and Resilience. Pediatrics 103, 1122–1127 (1999).

Compton WM, Thomas YF, Stinson FS & Grant BF. Prevalence, correlates, disability, and comorbidity of dsm-iv drug abuse and dependence in the united states: Results from the national epidemiologic survey on alcohol and related conditions. Arch. Gen. Psychiatry 64, 566–576 (2007).

Steiker, C. S. Lessons from Two Failures: Sentencing for Cocaine and Child Pornography under the Federal Sentencing Guidelines in the United States. Law Contemp. Probl. 76, 27 (2013).

Tonry, M. Remodeling American Sentencing: A Ten-Step Blueprint for Moving Past Mass Incarceration. Criminol. Public Policy 13, 503–533 (2014).

Nauman, S. Brown v. Plata: Renewing the Call to End Mandatory Minimum Sentencing. Fla. Law Rev. 65, 855 (2013).

Dumont, D. M., Brockmann, B., Dickman, S., Alexander, N. & Rich, J. D. Public Health and the Epidemic of Incarceration. Annu. Rev. Public Health 33, 325–339 (2012).

Degenhardt, L. et al. Effects of a sustained heroin shortage in three Australian States. Addiction 100, 908–920 (2005).

UNODC. Afghanistan opium survey 2015. (United Nations Office on Drugs and Crime, 2015).

Aspinall, E. J. et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int. J. Epidemiol. 43, 235–248 (2014).

Abdul-Quader, A. S. et al. Effectiveness of Structural-Level Needle/Syringe Programs to Reduce HCV and HIV Infection Among People Who Inject Drugs: A Systematic Review. AIDS Behav. 17, 2878–2892 (2013).

Des Jarlais, D. C., Feelemyer, J. P., Modi, S. N., Abdul-Quader, A. & Hagan, H. High coverage needle/syringe programs for people who inject drugs in low and middle income countries: a systematic review. BMC Public Health 13, 53 (2013).

MacArthur, G. J. et al. Interventions to prevent HIV and Hepatitis C in people who inject drugs: A review of reviews to assess evidence of effectiveness. Int. J. Drug Policy 25, 34–52 (2014).

Dutta, A., Wirtz, A. L., Baral, S., Beyrer, C. & Cleghorn, F. R. Key harm reduction interventions and their impact on the reduction of risky behavior and HIV incidence among people who inject drugs in low-income and middle-income countries. Curr. Opin. HIV AIDS 7, 362–368 (2012).

Des Jarlais, D. C. et al. Syringe Service Programs for Persons Who Inject Drugs in Urban, Suburban, and Rural Areas--United States, 2013. 1337–1341 (Center for Disease Control, 2015).

Wilson, D. P., Donald, B., Shattock, A. J., Wilson, D. & Fraser-Hurt, N. The cost-effectiveness of harm reduction. Int. J. Drug Policy 26, Supplement 1, S5–S11 (2015).

Office of National Drug Control Policy. 2015 National Drug Control Strategy. 2015 National Drug Control Strategy Available at: https://www.whitehouse.gov/ondcp/national-drug-control-strategy. (Accessed: 10th June 2016)

Centers for Disease Control and Prevention. Community-Based Opioid Overdose Prevention Programs Providing Naloxone — United States, 2010. (Centers for Disease Control and Prevention, 2012).

Commission on Narcotic Drugs. 2014 High-level Review by the Commission on Narcotic Drugs of the Implementation by Member States of the Political Declaration and Plan of Action on International Cooperation Towards an Integrated and Balanced Stratagy to Counter the World Drug Problem. (United Nations Office on Drugs and Crime, 2014).

Secretariat. Public health dimension of the world drug problem including in the context of the Special Session of the United Nations General Assembly on the World Drug Problem, to be held in 2016. (World Health Organization, 2016).

Garcia-Portilla, M. P., Bobes-Bascaran, M. T., Bascaran, M. T., Saiz, P. A. & Bobes, J. Long term outcomes of pharmacological treatments for opioid dependence: does methadone still lead the pack? Br. J. Clin. Pharmacol. 77, 272–284 (2014).

Cousins, G. et al. Risk of mortality on and off methadone substitution treatment in primary care: a national cohort study. Addiction 111, 73–82 (2016).

Otiashvili, D. et al. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior—Outcomes of a randomized trial. Drug Alcohol Depend. 133, 376–382 (2013).

Woody, G. E. et al. HIV Risk Reduction With Buprenorphine–Naloxone or Methadone: Findings From a Randomized Trial. JAIDS J. Acquir. Immune Defic. Syndr. 66, 288–293 (2014).

Alavian, S.-M. et al. Effectiveness of Methadone Maintenance Treatment in Prevention of Hepatitis C Virus Transmission among Injecting Drug Users. Hepat. Mon. 13, (2013).

Javanbakht, M., Mirahmadizadeh, A. & Mashayekhi, A. The Long-Term Effectiveness of Methadone Maintenance Treatment in Prevention of Hepatitis C Virus Among Illicit Drug Users: A Modeling Study. Iran. Red Crescent Med. J. 16, (2014).

Ball, J. C. & Ross, A. The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services, and Outcome. (Springer Science & Business Media, 2012).

Sun, H.-M. et al. Methadone maintenance treatment programme reduces criminal activity and improves social well-being of drug users in China: a systematic review and meta-analysis. BMJ Open 5, e005997 (2015).

National Institute of Justice. Drug Courts. National Institute of Justice (2016). Available at: http://www.nij.gov/topics/courts/drug-courts/pages/welcome.aspx.

Brown, R., Gassman, M., Hetzel, S. & Berger, L. Community-based treatment for opioid dependent offenders: A pilot study. Am. J. Addict. 22, 500–502 (2013).

Gottfredson, D. C., Najaka, S. S. & Kearley, B. Effectiveness of Drug Treatment Courts: Evidence from a Randomized Trial*. Criminol. Public Policy 2, 171–196 (2003).

Wilson, D. B., Mitchell, O. & MacKenzie, D. L. A systematic review of drug court effects on recidivism. J. Exp. Criminol. 2, 459–487 (2006).

Mitchell, O., Wilson, D. B., Eggers, A. & MacKenzie, D. L. Assessing the effectiveness of drug courts on recidivism: A meta-analytic review of traditional and non-traditional drug courts. J. Crim. Justice 40, 60–71 (2012).

Shannon, L. M., Jones, A. J., Newell, J. & Neal, C. Examining the Impact of Prior Criminal Justice History on 2-Year Recidivism Rates A Comparison of Drug Court Participants and Program Referrals. Int. J. Offender Ther. Comp. Criminol. (2016).

Spohn, C., Piper, R. K., Martin, T. & Frenzel, E. D. Drug Courts and Recidivism: The Results of an Evaluation Using Two Comparison Groups and Multiple Indicators of Recidivism. J. Drug Issues 31, 149–176 (2001).

Shaffer, D. K. RECONSIDERING DRUG COURT EFFECTIVENESS: A META-ANALYTIC REVIEW. (Thesis--University of Cincinnati, 2006).




DOI: http://dx.doi.org/10.18103/imr.v0i5.98

Refbacks

  • There are currently no refbacks.
Copyright 2016. All rights reserved.